<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-7-156</article-id><article-id pub-id-type="pmid">17692120</article-id><article-id pub-id-type="doi">10.1186/1471-2407-7-156</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Bacman</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>david_bacman2@yahoo.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Merkel</surname><given-names>Susanne</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>susanne.merkel@chir.imed.uni-erlangen.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Croner</surname><given-names>Roland</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>roland.croner@chir.imed.uni-erlangen.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Papadopoulos</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>thomas.papadopoulos@patho.imed.uni-erlangen.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Brueckl</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>wolfgang.brueckl@med1.imed.uni-erlangen.de</email></contrib><contrib id="A6" corresp="yes" contrib-type="author"><name><surname>Dimmler</surname><given-names>Arno</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>arno.dimmler@vincentius-ka.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Institute of Pathology, University of Erlangen-Nuremberg, Germany</aff><aff id="I2"><label>2</label>Department of Surgery, University of Erlangen-Nuremberg, Germany</aff><aff id="I3"><label>3</label>Department of Internal Medicine I, University of Erlangen-Nuremberg, Germany</aff><aff id="I4"><label>4</label>Institute of Pathology, St. Vincentius hospital, Karlsruhe, Germany</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>10</day><month>8</month><year>2007</year></pub-date><volume>7</volume><fpage>156</fpage><lpage>156</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/7/156"/><history><date date-type="received"><day>16</day><month>12</month><year>2006</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Bacman et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Bacman et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Bacman David david_bacman2@yahoo.de </dc:author><dc:title> TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Cancer 7(1): 156-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2007)7:1&#x0003c;156&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Histological phenotype and clinical behaviour of malignant tumours are not only dependent on alterations in the epithelial cell compartment, but are affected by their interaction with inflammatory cells and tumour-associated stroma. Studies in animal models have shown influence of tumour-associated macrophages (TAM) on histological grade of differentiation in colon carcinoma. Disruption of transforming growth factor beta (TGF-beta) signalling in tumour cells is related to more aggressive clinical behaviour. Expression data of components of this pathway in tumour-associated stroma is limited.</p></sec><sec sec-type="methods"><title>Methods</title><p>Tissue micro arrays of 310 colon carcinomas from curatively resected patients in UICC stage II and III were established. In a first step we quantified amount of CD68 positive TAMs and expression of components of TGF-beta signalling (TGF-beta1, TGF-beta receptors type 1 and 2, Smad 3 and 4) in tumour and associated stroma. Further we analyzed correlation to histological and clinical parameters (histological grade of differentiation (low-grade (i.e. grade 1 and 2) vs. high-grade (i.e. grade 3 and 4)), lymph node metastasis, distant metastasis, 5 year cancer related survival) using Chi-square or Fisher's exact test, when appropriate, to compare frequencies, Kaplan-Meier method to calculate 5-year rates of distant metastases and cancer-related survival and log rank test to compare the rates of distant metastases and survival. To identify independent prognostic factors Cox regression analysis including lymph node status and grading was performed.</p></sec><sec><title>Results</title><p>High-grade tumours and those with lymph node metastases showed higher rates of TAMs and lower expression of TGF-beta1. Loss of nuclear Smad4 expression in tumor was associated with presence of lymph node metastasis, but no influence on prognosis could be demonstrated. Decrease of both TGF-beta receptors in tumour-associated stroma was associated with increased lymph node metastasis and shorter survival. Stromal TGF-beta receptor 2 expression was an independent prognostic factor for cancer related survival.</p></sec><sec><title>Conclusion</title><p>Histological phenotype and clinical behaviour of colon cancer is not only influenced by mutational incidents in tumour cells but also affected by interaction of tumour tissue with inflammatory cells like macrophages and associated stroma and TGF-beta signalling is one important part of this crosstalk. Further studies are needed to elucidate the exact mechanisms.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Tumours do not exclusively consist of neoplastic epithelial cells, but are also accompanied by a stromal compartment composed of a variety of non-malignant cells, such as fibroblasts, inflammatory cells, and endothelial cells, as well as extracellular elements [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>] Nonetheless in the past cancer research has been focused primarily on oncogenic events in tumour cells. It has, however, become increasingly clear that the tumour environment plays an important role in malignant disease, and a correlation between (chronic) inflammation and human predisposition to carcinogenesis has been demonstrated in several malignancies [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>].</p><p>The majority of leukocytes that infiltrate the neoplastic stroma consist of macrophages, which are referred to as tumour-associated macrophages (TAMs)[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Clinical observations have shown that the presence of abundant TAMs can be associated with malignant behaviour in breast, prostatic, ovarian, and cervical carcinomas [<xref ref-type="bibr" rid="B4">4</xref>]. For other types of cancer, such as gastric, lung, and colorectal carcinomas, opposing data have been reported[<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. Thus, the biological significance and possible clinical implications of TAMs' presence are not yet fully understood.</p><p>Maintenance of epithelial tissues needs the stroma. When the epithelium changes, the stroma inevitably follows. Crosstalk between tumour and stromal compartment is based on several signalling pathways. One important cytokine in this context is transforming growth factor beta (TGF-&#x003b2;). The TGF-&#x003b2; superfamily of secreted polypeptides consists of three 25 kDa-proteins (TGF-&#x003b2;1, 2 and 3) and regulates cell proliferation, differentiation, motility, apoptosis and extracellular matrix formation in a variety of different cell types [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. TGF-&#x003b2; serves as a tumour suppressor pathway in the normal colon by inhibiting cell proliferation and inducing apoptosis [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. During late stages of colorectal carcinogenesis, TGF-&#x003b2; serves as a tumour promoter [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>] and is often over expressed. A high expression level of TGF-&#x003b2; in the primary tumour is associated with advanced stages[<xref ref-type="bibr" rid="B18">18</xref>], tumour recurrence [<xref ref-type="bibr" rid="B19">19</xref>], and decreased survival[<xref ref-type="bibr" rid="B18">18</xref>].</p><p>The TGF-&#x003b2; signal is transduced by a pair of transmembrane serine-threonine kinase receptors[<xref ref-type="bibr" rid="B11">11</xref>]. TGF-&#x003b2; binds primarily to TGF-&#x003b2;-R2 receptor homodimers, which then form heterotetrameric complexes with two TGF-&#x003b2;-R1 molecules. As a consequence, the TGF-&#x003b2;-R2 kinase phosphorylates TGF-&#x003b2;-R1, thereby activating its serine-threonine kinase. In response to receptor activation, two cytosolic proteins, Smad2 and Smad3, become transiently associated with and phosphorylated by the TGF-&#x003b2;-R1 kinase. After their activation, Smad2 and Smad3 form heteromeric complexes with a third homologue, Smad4. These complexes are translocated to the nucleus, bind to DNA in a sequence-specific manner, and regulate gene transcription[<xref ref-type="bibr" rid="B11">11</xref>]. The resulting repression of c-<italic>myc </italic>and induction of cyclin-dependent kinase inhibitors as well as cdc25A phosphatase lead to G<sub>1 </sub>phase cell cycle arrest.</p><p>Most colorectal cancers escape the tumour suppressor effects of TGF-&#x003b2; as demonstrated by their resistance to the antiproliferative and apoptotic effects of TGF-&#x003b2; [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. The molecular mechanisms by which colorectal cancers escape the tumour suppressor effects of TGF-&#x003b2; are an area of active investigation. A subset of colorectal cancers has been shown to have mutations or down-regulation of the type 1 receptor [<xref ref-type="bibr" rid="B20">20</xref>], type 2 receptor [<xref ref-type="bibr" rid="B21">21</xref>], Smad2 [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>] and Smad4 [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>].</p><p>Most studies so far focussed on alterations of the TGF-&#x003b2; pathway in the tumour cells. In the present study we investigated in addition to tumour-associated macrophages alterations of this signalling in tumour-associated desmoplastic stroma and their relation to histological tumour grade, regional and distant metastasis rates and survival in a group of colon carcinoma patients that underwent colon resection.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Tumour samples</title><p>Cases of colon adenocarcinomas were retrieved retrospectively from the files of the Department of Pathology at the University of Erlangen-Nuremberg, Germany. The specimen had been formalin-fixed, paraffin-embedded and tumour diagnosis made on haematoxylin and eosin (HE) sections. In the present study 310 tumour samples of patients were included, which underwent radical resection with formal regional lymph node dissection between 1991 and 2001 and received complete surgical resection of their colon carcinoma on clinical and pathohistological examination. Only solitary colon carcinomas except appendix tumours were included. Further exclusion criteria were: anamnestic or synchronous other malignant tumours, known familial adenomatous polyposis, colitis ulcerosa or Crohn's disease, neoadjuvant therapy, synchronous distant metastases, emergency operation, perioperative death and unknown tumour stage at the end of follow up. Clinical data is summarized in table <xref ref-type="table" rid="T1">1</xref>. The study was carried out in compliance with the Helsinki Declaration. Ethics Committee, Faculty of Medicine, University of Erlangen-Nuremberg approved research on anonymized archived tumor material of patients in a general statement from January 24<sup>th</sup>, 2005.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical data of included colon carcinoma patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">patient data</td><td></td></tr></thead><tbody><tr><td align="left">number of patients</td><td align="left">n = 310</td></tr><tr><td align="left">of these: male</td><td align="left">n = 189 (61%)</td></tr><tr><td align="left">female</td><td align="left">n = 121 (39%)</td></tr><tr><td align="left">median age</td><td align="left">64 y (range 28&#x02013;91 y)</td></tr><tr><td align="left">median follow up</td><td align="left">91 mo (range 1&#x02013;177 mo)</td></tr><tr><td align="left">adjuvant chemotherapy</td><td align="left">n = 48 (16%)</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="left">tumour site</td><td></td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="left">caecum</td><td align="left">n = 31 (10.0%)</td></tr><tr><td align="left">colon ascendens</td><td align="left">n = 51 (16.5%)</td></tr><tr><td align="left">flexura hepatica</td><td align="left">n = 21 (6.8%)</td></tr><tr><td align="left">colon transversum</td><td align="left">n = 32 (10.3%)</td></tr><tr><td align="left">flexura lienalis</td><td align="left">n = 15 (4.8%)</td></tr><tr><td align="left">colon descendens</td><td align="left">n = 14 (4.5%)</td></tr><tr><td align="left">colon sigmoideum</td><td align="left">n = 146 (47.1%)</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="left">tumour stage (UICC) or lymph node metastasis</td><td></td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="left">II or N0</td><td align="left">n = 178 (57.4%)</td></tr><tr><td align="left">III or N+</td><td align="left">n = 132 (42.6%)</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="left">grading</td><td></td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="left">low-grade (G1 and G2)</td><td align="left">n = 257 (82.9%)</td></tr><tr><td align="left">high-grade (G3 and G4)</td><td align="left">n = 53 (17.1%)</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="left">depth of invasion</td><td></td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="left">pT2</td><td align="left">n = 24 (7.7%)</td></tr><tr><td align="left">pT3</td><td align="left">n = 255 (82.3%)</td></tr><tr><td align="left">pT4</td><td align="left">n = 31 (10.0%)</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="left">distant metastasis after 5 years follow up</td><td align="left">n = 62 (20.0%)</td></tr></tbody></table></table-wrap></sec><sec><title>Tissue micro array technique</title><p>A map of the receiver blocks was prepared with coordinates for each sample to correctly identify the tumour samples. Under a microscope nonnecrotic carcinoma areas and surrounding areas of immediately adjacent desmoplastic stroma were marked with an indelible pen on the HE whole section of each donor block.</p><p>The tissue micro arrayer (Beecher Instruments, Woodland, USA) was used as follows: cores of 0.6 mm diameter were punched from the donor blocks and positioned in a recipient paraffin array block in smaller holes of 0.4 mm for best adhesion of the samples to the array block. Three cores of tonsil tissue were positioned on the upper left corner of each recipient block for correct orientation on the array of the recipient block. The array blocks were then incubated for 30 min at 37&#x000b0;C to improve adhesion between cores and paraffin of the recipient block. Afterwards the blocks were cut with a standard microtome (Microm, Heidelberg, Germany).</p></sec><sec><title>Immunohistochemistry</title><p>Sections of 5 &#x003bc;m from the fourteen tissue arrays were cut onto silane-treated Super Frost slides (CML, Nemours, France) and left to dry overnight. The slides were deparaffinized in xylene and rehydrated in pure ethanol. Endogenous peroxidase was blocked using 3 % hydrogen peroxide in methanol for 30 min. The slides were then placed in a microwave oven in citrate buffer (TGF-&#x003b2;1, TGF-&#x003b2;-R1, TGF-&#x003b2;-R2, Smad3, CD68) for 45 min at 120 to 85&#x000b0;C for antigen retrieval with a subsequent biotin-streptavidin-peroxidase detection technique or in TRS6 (DAKO, Hamburg, Germany) buffer (Smad4) at the same processing conditions with subsequent tyramide signal amplification coupled alkaline phosphatase (DAKO, Hamburg, Germany) -Fast Red (Sigma-Aldrich, Munich, Germany) detection technique. All slides were then processed manually. Antibodies to TGF-&#x003b2;1 (mouse anti-human monoclonal, clone TGFB17, dilution 1:20, Novo Castra, Newcastle upon Tyne, Great Britain), TGF-&#x003b2;-R1 (mouse anti-human monoclonal, clone 8A11, dilution 1:100, Novo Castra, Newcastle upon Tyne, Great Britain), TGF-&#x003b2;-R2 (goat anti-human polyclonal, AF-241-NA, dilution 1:100, Wiesbaden, Germany), Smad3 (rabbit anti-human polyclonal, 51&#x02013;500, dilution 1:200, Zymed, San Francisco, USA), Smad4 (mouse anti-human monoclonal, sc-7966, dilution 1:50, Santa Cruz Biotechnology, Heidelberg, Germany), CD68 (mouse anti-human monoclonal, clone PG-M1, dilution 1:200, DAKO, Hamburg, Germany) were used. The slides were counterstained with Mayer's haemalaun. To exclude non-specific reactions of secondary antibodies or the different detection systems control specimen were processed without primary antibodies. In the CD68 staining four categories of macrophage infiltration of the tumour tissue were assessed (none (0), mild (1), intermediate (2), strong (3), see fig. <xref ref-type="fig" rid="F1">1</xref>). In the TGF-&#x003b2;1 staining four degrees of cytoplasmatic staining intensity (none (0), mild (1), medium(2), strong (3), fig. <xref ref-type="fig" rid="F1">1</xref>) in tumour and surrounding stroma were assessed separately. For the TGF-&#x003b2;-R1 and TGF-&#x003b2;-R2 membranous staining the same four categories were applied (fig. <xref ref-type="fig" rid="F1">1</xref>). Presence or absence of nuclear and cytoplasmatic staining was assessed for Smad 3 and 4 in tumour and surrounding stroma (for examples [see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>]).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Immunohistochemical analysis of tumor and associated stroma</bold>. Examples for degree of TAM infiltration in CD68 staining and levels of expression of TGF-&#x003b2;1 and TGF-&#x003b2;-R2 in tumour and associated stroma. Note change of differentiation grade with increase in TAMs.</p></caption><graphic xlink:href="1471-2407-7-156-1"/></fig></sec><sec><title>Statistical analysis</title><p>The Kaplan-Meier method was used to calculate 5-year rates of distant metastases and cancer-related survival. The log rank test was used to compare the rates of distant metastases and survival. To identify independent prognostic factors Cox regression analysis including lymph node status and grading was performed. To compare frequencies Chi-square test, or Fisher's exact test when appropriate, was used. A p-value of less than 0.05 was considered to be significant. All analyses were performed using the statistical software SPSS for Windows Version 13 (SPSS Inc., Chicago, USA).</p></sec></sec><sec><title>Results</title><p>The results are summarized in table <xref ref-type="table" rid="T2">2</xref>.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Content of tumour-associated macrophages and expression of TGF-&#x003b2; components in tumour and -associated stroma</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">tumour</td><td align="center" colspan="2">TAMs</td><td></td><td align="center" colspan="2">TGF-&#x003b2;1</td><td></td><td align="center" colspan="2">TGF-&#x003b2;-R1</td><td></td><td align="center" colspan="2">TGF-&#x003b2;-R2</td><td></td><td align="center" colspan="2">Smad3</td><td></td><td align="center" colspan="2">Smad4</td><td></td></tr><tr><td align="center">n</td><td align="center">low (0&#x02013;1)</td><td align="center">high (2&#x02013;3)</td><td align="center">p value</td><td align="center">low (0&#x02013;1)</td><td align="center">high (2&#x02013;3)</td><td align="center">p value</td><td align="center">low (0&#x02013;1)</td><td align="center">high (2&#x02013;3)</td><td align="center">p value</td><td align="center">neg.</td><td align="center">pos.</td><td align="center">p value</td><td align="center">neg.</td><td align="center">pos.</td><td align="center">p value</td><td align="center">neg.</td><td align="center">pos.</td><td align="center">p value</td></tr></thead><tbody><tr><td align="center">low-grade</td><td align="center">248</td><td align="center">7</td><td align="center"><bold>&#x0003c;0.001</bold></td><td align="center">165</td><td align="center">90</td><td align="center"><bold>0.009</bold></td><td align="center">239</td><td align="center">16</td><td align="center">0.148</td><td align="center">245</td><td align="center">10</td><td align="center">0.278</td><td align="center">111</td><td align="center">146</td><td align="center">0.907</td><td align="center">39</td><td align="center">214</td><td align="center">0.295</td></tr><tr><td align="center">high-grade</td><td align="center">39</td><td align="center">13</td><td></td><td align="center">44</td><td align="center">9</td><td></td><td align="center">47</td><td align="center">7</td><td></td><td align="center">50</td><td align="center">4</td><td></td><td align="center">22</td><td align="center">30</td><td></td><td align="center">5</td><td align="center">47</td><td></td></tr><tr><td align="center">N0</td><td align="center">167</td><td align="center">9</td><td align="center"><bold>0.019</bold></td><td align="center">113</td><td align="center">63</td><td align="center">0.202</td><td align="center">163</td><td align="center">14</td><td align="center">0.581</td><td align="center">167</td><td align="center">10</td><td align="center">0.630</td><td align="center">79</td><td align="center">99</td><td align="center">0.579</td><td align="center">35</td><td align="center">139</td><td align="center"><bold>0.004</bold></td></tr><tr><td align="center">N+</td><td align="center">120</td><td align="center">11</td><td></td><td align="center">96</td><td align="center">36</td><td></td><td align="center">123</td><td align="center">9</td><td></td><td align="center">128</td><td align="center">4</td><td></td><td align="center">54</td><td align="center">77</td><td></td><td align="center">9</td><td align="center">122</td><td></td></tr><tr><td align="center">5 ycrs</td><td align="center">87.0</td><td align="center">80.0</td><td align="center">0.261</td><td align="center">85.6</td><td align="center">88.8</td><td align="center">0.459</td><td align="center">86.4</td><td align="center">87.0</td><td align="center">0.787</td><td align="center">87.0</td><td align="center">78.6</td><td align="center">0.631</td><td align="center">86.1</td><td align="center">86.6</td><td align="center">0.991</td><td align="center">92.5</td><td align="center">85.4</td><td align="center">0.896</td></tr><tr><td align="center">5 ydm</td><td align="center">19.4</td><td align="center">30.0</td><td align="center">0.241</td><td align="center">18.7</td><td align="center">22.6</td><td align="center">0.463</td><td align="center">19.9</td><td align="center">17.4</td><td align="center">0.851</td><td align="center">19.9</td><td align="center">21.4</td><td align="center">0.701</td><td align="center">19.5</td><td align="center">19.9</td><td align="center">0.795</td><td align="center">17.3</td><td align="center">20.7</td><td align="center">0.419</td></tr><tr><td colspan="19"><hr></hr></td></tr><tr><td align="center">stroma</td><td align="center" colspan="2">TAMs</td><td></td><td align="center" colspan="2">TGF-&#x003b2;1</td><td></td><td align="center" colspan="2">TGF-&#x003b2;-R1</td><td></td><td align="center" colspan="2">TGF-&#x003b2;-R2</td><td></td><td align="center" colspan="2">Smad3</td><td></td><td align="center" colspan="2">Smad4</td><td></td></tr><tr><td align="center">n</td><td align="center">low (0&#x02013;1)</td><td align="center">high (2&#x02013;3)</td><td align="center">p value</td><td align="center">low (0&#x02013;1)</td><td align="center">high (2&#x02013;3)</td><td align="center">p value</td><td align="center">low (0&#x02013;1)</td><td align="center">high (2&#x02013;3)</td><td align="center">p value</td><td align="center">neg.</td><td align="center">pos.</td><td align="center">p value</td><td align="center">neg.</td><td align="center">pos.</td><td align="center">p value</td><td align="center">neg.</td><td align="center">pos.</td><td align="center">p value</td></tr><tr><td colspan="19"><hr></hr></td></tr><tr><td align="center">low-grade</td><td align="center">152</td><td align="center">104</td><td align="center">0.134</td><td align="center">256</td><td align="center">0</td><td align="center">n.a.</td><td align="center">162</td><td align="center">94</td><td align="center">1.000</td><td align="center">98</td><td align="center">158</td><td align="center">0.229</td><td align="center">140</td><td align="center">117</td><td align="center">0.653</td><td align="center">7</td><td align="center">249</td><td align="center">1.000</td></tr><tr><td align="center">high-grade</td><td align="center">26</td><td align="center">28</td><td></td><td align="center">52</td><td align="center">0</td><td></td><td align="center">34</td><td align="center">20</td><td></td><td align="center">25</td><td align="center">28</td><td></td><td align="center">27</td><td align="center">26</td><td></td><td align="center">1</td><td align="center">52</td><td></td></tr><tr><td align="center">N0</td><td align="center">59</td><td align="center">39</td><td align="center">0.141</td><td align="center">176</td><td align="center">0</td><td align="center">n.a.</td><td align="center">102</td><td align="center">76</td><td align="center"><bold>0.033</bold></td><td align="center">56</td><td align="center">121</td><td align="center"><bold>0.001</bold></td><td align="center">98</td><td align="center">80</td><td align="center">0.627</td><td align="center">5</td><td align="center">172</td><td align="center">1.000</td></tr><tr><td align="center">N+</td><td align="center">119</td><td align="center">93</td><td></td><td align="center">132</td><td align="center">0</td><td></td><td align="center">94</td><td align="center">38</td><td></td><td align="center">67</td><td align="center">65</td><td></td><td align="center">69</td><td align="center">63</td><td></td><td align="center">3</td><td align="center">129</td><td></td></tr><tr><td align="center">5 ycrs</td><td align="center">84.1</td><td align="center">87.8</td><td align="center">0.897</td><td align="center">86.4</td><td align="center">n.a.</td><td align="center">n.a.</td><td align="center">84.7</td><td align="center">89.5</td><td align="center">0.245</td><td align="center">82.3</td><td align="center">89.3</td><td align="center"><bold>0.003</bold></td><td align="center">87.5</td><td align="center">85.4</td><td align="center">0.753</td><td align="center">83.3</td><td align="center">86.5</td><td align="center">0.812</td></tr><tr><td align="center">5 ydm</td><td align="center">12.6</td><td align="center">20.0</td><td align="center">0.643</td><td align="center">20.7</td><td align="center">n.a.</td><td align="center">n.a.</td><td align="center">24.5</td><td align="center">12.3</td><td align="center">0.072</td><td align="center">25.4</td><td align="center">16.6</td><td align="center">0.087</td><td align="center">21.0</td><td align="center">18.9</td><td align="center">0.392</td><td align="center">14.3</td><td align="center">20.2</td><td align="center">0.582</td></tr></tbody></table><table-wrap-foot><p>5 ycr: 5 year cancer related survival (%); 5 ydm: 5 year rate of distant metastasis (%); n.a.: not available.</p></table-wrap-foot></table-wrap><sec><title>TAMs</title><p>Macrophages in tumour-associated stroma were more abundant than those infiltrating tumour tissue (mean score 1.8 vs. 0.5). We found significantly higher levels of tumour-associated macrophages in high-grade tumours (p &#x0003c; 0.001) and tumours with lymph node metastases (p = 0.019). 58% (167 of 287) of tumours with no or only mild infiltration by TAMs compared to 45% (9 of 20) of tumours showing intermediate and strong infiltration had no lymph node metastases. There were no significant differences in 5-year survival (87% vs. 80%) or distant metastases (19.4% vs. 30.0%) between the two groups (p = 0.261 and p = 0.241 respectively).</p></sec><sec><title>Components of TGF-&#x003b2; pathway in tumour tissue</title><p>In 296 of 308 tumours (96%) expression of TGF-&#x003b2;1 could be demonstrated. Low-grade tumours showed higher TGF-&#x003b2;1 expression (p = 0.009; mean expression level 1.40 for low-grade vs. 0.91 for high-grade tumours). No correlation between TGF-&#x003b2;1 expression and lymph node metastasis, cancer related survival or distant metastasis could be demonstrated.</p><p>Only few tumours showed expression of TGF-&#x003b2; receptors (27% or 84 of 309 for type1; 5% or 14 of 295 for type 2). The rate of receptor expression was not linked to histological grade, regional or distant metastasis or survival.</p><p>In the majority of tumours (nuclear or cytoplasmatic) expression of Smad3 (91%; 279 of 309 tumours) and Smad4 (100% or all 305 tumours) was found. Most tumours showed nuclear expression of Smad3 (57%; 176 of 309) and Smad4 (86%; 261 of 305), but no correlation to histological grade could be demonstrated. More nodal positive tumours (93% or 122 of 131) than cases without lymph node metastasis (80% or 139 of 174) showed nuclear Smad4 expression (p = 0.004). No correlation was found between expression of Smads and distant metastasis or survival.</p></sec><sec><title>Components of TGF-&#x003b2; pathway in tumour-associated stroma</title><p>Expression of TGF-&#x003b2;1 in tumour-associated stroma could not be demonstrated. Expression of TGF-&#x003b2; receptors and Smads in stroma was restricted to spindled and sometimes stellar stromal cells apparently representing fibroblasts and myofibroblasts. In most cases TGF-&#x003b2; receptors were expressed in the tumour-associated stroma (60% or 188 of 310 for type 1; 60% or 186 of 309 for type 2). For both receptors no correlation to histological grade was found. Higher TGF-&#x003b2; receptor expression in stroma was associated with significant decrease of nodal positive tumours (table <xref ref-type="table" rid="T2">2</xref>, p = 0.033 for type 1 and p = 0.001 for type 2). This was partially reflected by significantly better 5-year cancer related survival for receptor positive compared to negative cases in the nodal positive group (type 1: 86% vs. 69%; p = 0.011 and type 2: 83% vs.76%; p = 0.032). TGF-&#x003b2; receptor expressing cases showed a trend towards lower rates of distant metastasis, although this difference was not significant (table <xref ref-type="table" rid="T2">2</xref>; 24.5% vs. 12.3%; p = 0.072 for type 1 and 25.4% vs. 16.6%, p = 0.087 for type 2).</p><p>Nuclear expression in the stroma was detected in 46% (143 of 310) of tumours for Smad3 and 97% (301 of 309) for Smad4. No correlation to histological grade, local and distant metastasis or survival could be demonstrated.</p></sec><sec><title>Multivariate analysis</title><p>In univariate analysis using log rank test presence of lymph node metastasis (identical to tumour stage: 5-year cancer-related survival rate: N0 or II: 92.1% vs. N+ or III: 79.5%, p &#x0003c;0,001, table <xref ref-type="table" rid="T3">3</xref>), vessel infiltration (V0: 89.0% vs. V1: 58.3%, p &#x0003c; 0,001) and TGF-&#x003b2;-R2 expression in tumour-associated stroma (negative: 82.3% vs. positive: 89.3%, p = 0,003) showed statistically significant correlation to cancer-related survival, whereas for all other factors no association could be demonstrated (see table <xref ref-type="table" rid="T3">3</xref>). On multivariate analysis using Cox regression analysis besides vessel infiltration and lymph node status expression of TGF-&#x003b2;-R2 in the stroma (RR 2.2, 95%CI 1.2&#x02013;3.8, p = 0.007, table <xref ref-type="table" rid="T3">3</xref>) was an independent prognostic factor for cancer-related survival as reflected in Kaplan-Meier survival curve (see Fig. <xref ref-type="fig" rid="F2">2</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Results of univariate and multivariate analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="5">univariate analysis</td></tr></thead><tbody><tr><td></td><td align="left">score</td><td align="left">n</td><td align="left">5 year survival rate</td><td align="left">SE</td><td align="left">p value</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">pT</td><td align="left">2</td><td align="left">24</td><td align="left">100</td><td></td><td align="left">0.226</td></tr><tr><td></td><td align="left">3</td><td align="left">255</td><td align="left">85.6</td><td align="left">2.2</td><td></td></tr><tr><td></td><td align="left">4</td><td align="left">31</td><td align="left">83.0</td><td align="left">6.9</td><td></td></tr><tr><td align="left">grading</td><td align="left">low-grade</td><td align="left">257</td><td align="left">86.9</td><td align="left">2.2</td><td align="left">0.446</td></tr><tr><td></td><td align="left">high-grade</td><td align="left">53</td><td align="left">84.8</td><td align="left">5</td><td></td></tr><tr><td align="left">lymph node status</td><td align="left">N0 or II</td><td align="left">178</td><td align="left">92.1</td><td align="left">2.1</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">or stage</td><td align="left">N+ or III</td><td align="left">132</td><td align="left">79.5</td><td align="left">3.5</td><td></td></tr><tr><td align="left">vessel infiltration</td><td align="left">V0</td><td align="left">285</td><td align="left">89.0</td><td align="left">1.9</td><td align="left">&#x0003c;0.001</td></tr><tr><td></td><td align="left">V1</td><td align="left">24</td><td align="left">58.3</td><td align="left">10.1</td><td></td></tr><tr><td align="left">chemotherapy</td><td align="left">applied</td><td align="left">261</td><td align="left">87.1</td><td align="left">2.1</td><td align="left">0.700</td></tr><tr><td></td><td align="left">not applied</td><td align="left">49</td><td align="left">83.5</td><td align="left">5.3</td><td></td></tr><tr><td align="left">TGF-&#x003b2;1 in tumour</td><td align="left">low (0&#x02013;1)</td><td align="left">209</td><td align="left">85.5</td><td align="left">2.5</td><td align="left">0.462</td></tr><tr><td></td><td align="left">high (2&#x02013;3)</td><td align="left">99</td><td align="left">88.6</td><td align="left">3.2</td><td></td></tr><tr><td align="left">Smad3 in tumour</td><td align="left">negative</td><td align="left">133</td><td align="left">88.1</td><td align="left">2.9</td><td align="left">0.941</td></tr><tr><td></td><td align="left">positive</td><td align="left">176</td><td align="left">85.3</td><td align="left">2.7</td><td></td></tr><tr><td align="left">Smad4 in tumour</td><td align="left">negative</td><td align="left">44</td><td align="left">92.5</td><td align="left">4.2</td><td align="left">0.896</td></tr><tr><td></td><td align="left">positive</td><td align="left">261</td><td align="left">85.4</td><td align="left">2.2</td><td></td></tr><tr><td align="left">TGF-&#x003b2;-R1 in stroma</td><td align="left">negative</td><td align="left">122</td><td align="left">83.8</td><td align="left">3.4</td><td align="left">0.121</td></tr><tr><td></td><td align="left">positive</td><td align="left">188</td><td align="left">88.3</td><td align="left">2.4</td><td></td></tr><tr><td align="left">TGF-&#x003b2; R2 in stroma</td><td align="left">negative</td><td align="left">123</td><td align="left">82.3</td><td align="left">3.5</td><td align="left">0.003</td></tr><tr><td></td><td align="left">positive</td><td align="left">186</td><td align="left">89.3</td><td align="left">2.3</td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td></td><td align="center" colspan="5">multivariate analysis</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td></td><td align="left">score</td><td align="left">n</td><td align="left">relative risk RR</td><td align="left">95% confidence intervall</td><td align="left">p value</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">TGF-&#x003b2; R2 in stroma</td><td align="left">negative</td><td align="left">122</td><td align="left">1</td><td></td><td></td></tr><tr><td></td><td align="left">positive</td><td align="left">186</td><td align="left">2.2</td><td align="left">1.2&#x02013;3.8</td><td align="left">0.007</td></tr><tr><td align="left">lymph node status</td><td align="left">N0</td><td align="left">177</td><td align="left">1</td><td></td><td></td></tr><tr><td></td><td align="left">N+</td><td align="left">131</td><td align="left">2.1</td><td align="left">1.2&#x02013;3.8</td><td align="left">0.012</td></tr><tr><td align="left">vessel infiltration</td><td align="left">V0</td><td align="left">284</td><td align="left">1</td><td></td><td></td></tr><tr><td></td><td align="left">V1</td><td align="left">24</td><td align="left">4.1</td><td align="left">2.1&#x02013;7.9</td><td align="left">&#x0003c;0.001</td></tr></tbody></table></table-wrap><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Kaplan-Meier survival curve for TGF-&#x003b2;-R2 expression in tumor-associated stroma</bold>. Cancer-related survival of colon carcinoma patients according to TGF-&#x003b2;-R2 expression in tumour-associated stroma.</p></caption><graphic xlink:href="1471-2407-7-156-2"/></fig></sec></sec><sec><title>Discussion</title><p>Macrophage functions are profoundly affected by micro-environmental signals and can range from powerful induction of inflammatory responses to immunosuppression [<xref ref-type="bibr" rid="B27">27</xref>]. Although it has been demonstrated previously that macrophages are capable of killing tumour cells <italic>in vitro </italic>and <italic>in vivo</italic>, evidence is now emerging in support of a tumour-promoting role for macrophages, and it has recently been hypothesized that macrophages, residing within neoplastic tissues, are educated by tumour cells to perform auxiliary oncogenic functions such as matrix break-down and induction of angiogenesis [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B30">30</xref>]. In the present study we found higher levels of TAMs in high-grade tumours and tumours with lymph node metastasis. Although there was a trend towards lower rates of distant metastasis and better survival rates in TAM rich tumours, this difference was not statistically significant. As this group accounts for less than 7% of tumours in our study this result might not be reproducible in larger series. Nonetheless several observations could explain these apparently contradictory effects of macrophages in disease outcome. In a recent experimental study the level of macrophage accumulation was found to correlate with macrophage functionality: high-level secretion of monocyte chemoattractant protein-1 (MCP-1) resulted in massive infiltration of macrophages with subsequent tumour regression. By contrast, low-level secretion of MCP-1 led to moderate infiltration of macrophages and melanoma progression [<xref ref-type="bibr" rid="B31">31</xref>]. Second, macrophage activity may alter over time as a consequence of tumour-induced immune dysfunction, since nitric oxide production, which is a major effector molecule for tumour cell killing, was suppressed in macrophages of tumour-bearing mice [<xref ref-type="bibr" rid="B32">32</xref>]. Third, a conceptual framework referred to as the so called macrophage balance hypothesis has been proposed, defining two different macrophage populations ranging from polarized potent killer/effector M1 cells to alternatively activated M2 macrophages with tumour-promoting characteristics. In a recently published study, the presence of macrophages directed tumours towards a histologically more malignant phenotype characterized by extensive stromal reaction, disorganized matrix deposition, and neovascularization [<xref ref-type="bibr" rid="B33">33</xref>]. Nonetheless, depletion of macrophages deprived tumour inhibitory functions as well, resulting in enhanced growth and decreased survival, emphasizing the complexity of the proposed macrophage balance. We think balance between the following actions of tumour-associated macrophages could account for some observations in the present study: At the primary tumour site macrophage dependent and cytokine mediated promoting activity might increase local infiltrative growth, enhancement of lymphangiogenesis and lymphatic vessel infiltration. On the other hand tumouricidal activity of macrophages might be restricted to single and isolated tumour cells on invasion front and founder cells of early hematogenic metastases. Reducing the number of macrophages per se, which has been proposed as a therapeutic strategy, may therefore not constitute the most optimal approach. However, specifically counteracting tumour-promoting characteristics and/or enhancing macrophage tumouricidal activity might be promising for future therapies. The second question we addressed in this study was whether alterations in TGF-&#x003b2; signalling are related to histological tumour grade and clinical behaviour of colon cancers. First we analyzed important factors of TGF-&#x003b2; signalling pathway in the epithelial component of the tumours. Immunostainable TGF-&#x003b2;1 has been detected in the malignant epithelial cells in the majority of our investigated cases of colon carcinomas and expression was shown to be higher in low-grade tumours, as shown recently [<xref ref-type="bibr" rid="B34">34</xref>], whereas we found no correlation to lymph node metastases, tumour stage or survival, although there was a non-significant trend towards lower TGF-&#x003b2;1 expression in tumours with regional lymph node metastases. This is in contrast to studies, where TGF-&#x003b2;1 overexpression in advanced stages of colorectal cancers has been reported and the intensity of the staining seems to correlate with advancing stages of tumour progression[<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. However, interpretation of these studies is complicated by difficulties associated with distinguishing the biologically inactive, latent form of TGF-&#x003b2;1 from its activated form.</p><p>Most tumours in the present study showed no detectable TGF-&#x003b2; receptor expression. The loss of TGF-&#x003b2; receptor expression in colon cancer either through mutation or downregulation has been reported [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>], but like in our study no correlation to histological grade or clinical outcome was found[<xref ref-type="bibr" rid="B37">37</xref>]. In contrast to loss of TGF-&#x003b2; receptors in tumour tissue we found frequent activation of Smad signalling indicated by nuclear expression of Smad3 and Smad4 in tumour and surrounding stroma, but only nuclear expression of Smad4 in the malignant epithelial component was correlated to presence of lymph node metastasis. Although experimental data suggest tumour suppressive effects of functionally active Smad4[<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B39">39</xref>] and loss of Smad4 in colorectal cancer is associated with advanced stage disease, presence of lymph node metastasis and poor prognosis [<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B43">43</xref>], others reported retained Smad4 expression in high-grade colorectal carcinoma and suggested loss of Smad4 is a late event in colorectal carcinogenesis [<xref ref-type="bibr" rid="B44">44</xref>]. In our study no influence of reduced Smad4 expression on prognosis was found. A possible explanation could be that in our study nodal positive cases (i.e. stage III patients) had an excellent 5 year survival of almost 80% indicating good local tumor control. The reduction of local recurrences possibly through extended lymphadenectomy could eliminate the prognostic influence of reduced Smad4. Activation of Smad signalling in our cases as indicated by frequent nuclear expression in the absence of TGF-&#x003b2;-R expression might occur primarily through TGF-&#x003b2; independent mechanisms, e.g. activin signalling [<xref ref-type="bibr" rid="B45">45</xref>]. Most authors so far focused primarily on the malignant epithelial component in tumours, so expression data of components of TGF-&#x003b2; pathway in tumour-associated stroma is rare. Unlike others [<xref ref-type="bibr" rid="B21">21</xref>] we found no expression of TGF-&#x003b2;1 in stroma. In our study frequent nuclear expression of Smads showed no correlation to tumour grade or clinical outcome. The most important finding in our study was an association of expression of both TGF-&#x003b2; receptors to presence of regional metastases. In patients with regional metastasized tumours decreased receptor expression in tumour-associated stroma was associated with shorter survival, whereas incidence of distant metastases showed only minor non-significant increase. Most importantly besides the well-established influence of lymph node metastasis and vessel infiltration on cancer-related survival in our study we were able to show that TGF-&#x003b2;-R2 expression in the stroma is an independent prognostic factor. Main effector cells for TGF-&#x003b2;1 in tumour-associated stroma are fibroblasts and myofibroblasts and decrease of TGF-&#x003b2; receptor expression in stroma as in epithelial tumour tissue might occur via mutation or downregulation [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>] and reflects functional alteration of TGF-&#x003b2; signalling. Paracrine effects of TGF-&#x003b2; in the stroma can be summarized as locally tumour promoting and implicate stimulation of angiogenesis, escape from immunosurveillance and recruitment of myofibroblasts (as reviewed in [<xref ref-type="bibr" rid="B46">46</xref>]). As in models of tumour escape from chemotherapy[<xref ref-type="bibr" rid="B47">47</xref>], disruption of TGF-&#x003b2; signalling in the stroma via decreased receptor expression might drive tumour evolution towards a prometastatic phenotype. This might account for decreased survival, although other mechanisms, e.g. reduction of indirect antiproliferative TGF-&#x003b2; feedback effects from stroma to tumour, are conceivable.</p></sec><sec><title>Conclusion</title><p>In summary not only mutational incidents in tumour cells but also interaction of tumour tissue with inflammatory cells like macrophages and associated stroma through TGF-&#x003b2; signalling modulates histological phenotype and clinical progression in colorectal cancer. Further studies are needed to clarify the underlying mechanisms.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>DB carried out assembly of tissue micro arrays and immunohistochemical stainings including evaluation and was involved in preparation of the manuscript. RC participated in the design of the study and was responsible for collection of clinical data. TP participated in the design of the study and coordination and helped to draft the manuscript. SM participated in the design of the study and performed the statistical analysis. WB participated in the design of the study and selection of patients. AD conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/7/156/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>Smad3 and Smad4 expression in tumour. The figure shows examples of immunohistochemical stainings of Smad3 and Smad 4 in tissue micro arrays. Tumours with loss of Smad4 expression were not found.</p></caption><media xlink:href="1471-2407-7-156-S1.jpeg" mimetype="image" mime-subtype="jpeg"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>The excellent technical assistance of Alexandra Geiger and Claudia Winkelmann is greatly acknowledged. The authors thank Gertrud Zimmermann for fruitful discussions and her unweary support of the study.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balkwill</surname><given-names>F</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Inflammation and cancer: back to Virchow?</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">11229684</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04046-0</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Inflammation and cancer</article-title><source>Nature</source><year>2002</year><volume>420</volume><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">12490959</pub-id><pub-id pub-id-type="doi">10.1038/nature01322</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leek</surname><given-names>RD</given-names></name><name><surname>Lewis</surname><given-names>CE</given-names></name><name><surname>Whitehouse</surname><given-names>R</given-names></name><name><surname>Greenall</surname><given-names>M</given-names></name><name><surname>Clarke</surname><given-names>J</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><article-title>Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>4625</fpage><lpage>4629</lpage><pub-id pub-id-type="pmid">8840975</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bingle</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>NJ</given-names></name><name><surname>Lewis</surname><given-names>CE</given-names></name></person-group><article-title>The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies</article-title><source>J Pathol</source><year>2002</year><volume>196</volume><fpage>254</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">11857487</pub-id><pub-id pub-id-type="doi">10.1002/path.1027</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Inflammatory cells and cancer: think different!</article-title><source>J Exp Med</source><year>2001</year><volume>193</volume><fpage>F23</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11257144</pub-id><pub-id pub-id-type="doi">10.1084/jem.193.6.F23</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Bottazzi</surname><given-names>B</given-names></name><name><surname>Colotta</surname><given-names>F</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name><name><surname>Ruco</surname><given-names>L</given-names></name></person-group><article-title>The origin and function of tumor-associated macrophages</article-title><source>Immunol Today</source><year>1992</year><volume>13</volume><fpage>265</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">1388654</pub-id><pub-id pub-id-type="doi">10.1016/0167-5699(92)90008-U</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohno</surname><given-names>S</given-names></name><name><surname>Inagawa</surname><given-names>H</given-names></name><name><surname>Dhar</surname><given-names>DK</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Ueda</surname><given-names>S</given-names></name><name><surname>Tachibana</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Soma</surname><given-names>G</given-names></name><name><surname>Nagasue</surname><given-names>N</given-names></name></person-group><article-title>The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients</article-title><source>Anticancer Res</source><year>2003</year><volume>23</volume><fpage>5015</fpage><lpage>5022</lpage><pub-id pub-id-type="pmid">14981961</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kataki</surname><given-names>A</given-names></name><name><surname>Scheid</surname><given-names>P</given-names></name><name><surname>Piet</surname><given-names>M</given-names></name><name><surname>Marie</surname><given-names>B</given-names></name><name><surname>Martinet</surname><given-names>N</given-names></name><name><surname>Martinet</surname><given-names>Y</given-names></name><name><surname>Vignaud</surname><given-names>JM</given-names></name></person-group><article-title>Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression</article-title><source>J Lab Clin Med</source><year>2002</year><volume>140</volume><fpage>320</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">12434133</pub-id><pub-id pub-id-type="doi">10.1067/mlc.2002.128317</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>Y</given-names></name><name><surname>Nagashima</surname><given-names>N</given-names></name><name><surname>Minagawa</surname><given-names>N</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Katsuki</surname><given-names>T</given-names></name><name><surname>Onitsuka</surname><given-names>K</given-names></name><name><surname>Sako</surname><given-names>T</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name><name><surname>Nagata</surname><given-names>N</given-names></name><name><surname>Itoh</surname><given-names>H</given-names></name></person-group><article-title>Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer</article-title><source>Anticancer Res</source><year>2002</year><volume>22</volume><fpage>4291</fpage><lpage>4296</lpage><pub-id pub-id-type="pmid">12553072</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>AB</given-names></name><name><surname>Anzano</surname><given-names>MA</given-names></name><name><surname>Wakefield</surname><given-names>LM</given-names></name><name><surname>Roche</surname><given-names>NS</given-names></name><name><surname>Stern</surname><given-names>DF</given-names></name><name><surname>Sporn</surname><given-names>MB</given-names></name></person-group><article-title>Type beta transforming growth factor: a bifunctional regulator of cellular growth</article-title><source>Proc Natl Acad Sci U S A</source><year>1985</year><volume>82</volume><fpage>119</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">3871521</pub-id><pub-id pub-id-type="doi">10.1073/pnas.82.1.119</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Massague</surname><given-names>J</given-names></name></person-group><article-title>TGF-beta signal transduction</article-title><source>Annu Rev Biochem</source><year>1998</year><volume>67</volume><fpage>753</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">9759503</pub-id><pub-id pub-id-type="doi">10.1146/annurev.biochem.67.1.753</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Derynck</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>XH</given-names></name></person-group><article-title>TGF-beta receptor signaling</article-title><source>Biochim Biophys Acta</source><year>1997</year><volume>1333</volume><fpage>F105</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">9395284</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>TC</given-names></name><name><surname>Beauchamp</surname><given-names>RD</given-names></name><name><surname>Townsend</surname><given-names>CM</given-names><suffix>Jr.</suffix></name><name><surname>Thompson</surname><given-names>EA</given-names></name><name><surname>Thompson</surname><given-names>JC</given-names></name></person-group><article-title>Transforming growth factor-beta inhibits rat intestinal cell growth by regulating cell cycle specific gene expression</article-title><source>Am J Surg</source><year>1994</year><volume>167</volume><fpage>14</fpage><lpage>9; discussion 19-20</lpage><pub-id pub-id-type="pmid">8311125</pub-id><pub-id pub-id-type="doi">10.1016/0002-9610(94)90048-5</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>TC</given-names></name><name><surname>Sheng</surname><given-names>HM</given-names></name><name><surname>Reisman</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>EA</given-names></name><name><surname>Beauchamp</surname><given-names>RD</given-names></name></person-group><article-title>Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells</article-title><source>Oncogene</source><year>1995</year><volume>10</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">7824270</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conery</surname><given-names>AR</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Thompson</surname><given-names>EA</given-names></name><name><surname>Townsend</surname><given-names>CM</given-names><suffix>Jr.</suffix></name><name><surname>Ko</surname><given-names>TC</given-names></name><name><surname>Luo</surname><given-names>K</given-names></name></person-group><article-title>Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis</article-title><source>Nat Cell Biol</source><year>2004</year><volume>6</volume><fpage>366</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">15104092</pub-id><pub-id pub-id-type="doi">10.1038/ncb1117</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Derynck</surname><given-names>R</given-names></name><name><surname>Akhurst</surname><given-names>RJ</given-names></name><name><surname>Balmain</surname><given-names>A</given-names></name></person-group><article-title>TGF-beta signaling in tumor suppression and cancer progression</article-title><source>Nat Genet</source><year>2001</year><volume>29</volume><fpage>117</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">11586292</pub-id><pub-id pub-id-type="doi">10.1038/ng1001-117</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akhurst</surname><given-names>RJ</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group><article-title>TGF-beta signaling in cancer--a double-edged sword</article-title><source>Trends Cell Biol</source><year>2001</year><volume>11</volume><fpage>S44</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">11684442</pub-id><pub-id pub-id-type="doi">10.1016/S0962-8924(01)02130-4</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>H</given-names></name><name><surname>Anderson</surname><given-names>E</given-names></name><name><surname>James</surname><given-names>RD</given-names></name><name><surname>Schofield</surname><given-names>PF</given-names></name></person-group><article-title>Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients</article-title><source>Br J Cancer</source><year>1996</year><volume>74</volume><fpage>753</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">8795578</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>E</given-names></name><name><surname>Gold</surname><given-names>LI</given-names></name><name><surname>Klimstra</surname><given-names>D</given-names></name><name><surname>Zeng</surname><given-names>ZS</given-names></name><name><surname>Winawer</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>A</given-names></name></person-group><article-title>High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>1995</year><volume>4</volume><fpage>549</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">7549813</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Zborowska</surname><given-names>E</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Willson</surname><given-names>JK</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Brattain</surname><given-names>MG</given-names></name></person-group><article-title>Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>17366</fpage><lpage>17371</lpage><pub-id pub-id-type="pmid">8663343</pub-id><pub-id pub-id-type="doi">10.1074/jbc.271.29.17366</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Matsuzaki</surname><given-names>K</given-names></name><name><surname>Date</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Shibano</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Yanagitani</surname><given-names>S</given-names></name><name><surname>Amoh</surname><given-names>Y</given-names></name><name><surname>Takemoto</surname><given-names>H</given-names></name><name><surname>Ogata</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>C</given-names></name><name><surname>Kubota</surname><given-names>Y</given-names></name><name><surname>Seki</surname><given-names>T</given-names></name><name><surname>Inokuchi</surname><given-names>H</given-names></name><name><surname>Nishizawa</surname><given-names>M</given-names></name><name><surname>Takada</surname><given-names>H</given-names></name><name><surname>Sawamura</surname><given-names>T</given-names></name><name><surname>Okamura</surname><given-names>A</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name></person-group><article-title>Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development</article-title><source>Br J Cancer</source><year>1999</year><volume>80</volume><fpage>194</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">10389996</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6690339</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riggins</surname><given-names>GJ</given-names></name><name><surname>Thiagalingam</surname><given-names>S</given-names></name><name><surname>Rozenblum</surname><given-names>E</given-names></name><name><surname>Weinstein</surname><given-names>CL</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><name><surname>Willson</surname><given-names>JK</given-names></name><name><surname>Markowitz</surname><given-names>SD</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><article-title>Mad-related genes in the human</article-title><source>Nat Genet</source><year>1996</year><volume>13</volume><fpage>347</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">8673135</pub-id><pub-id pub-id-type="doi">10.1038/ng0796-347</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eppert</surname><given-names>K</given-names></name><name><surname>Scherer</surname><given-names>SW</given-names></name><name><surname>Ozcelik</surname><given-names>H</given-names></name><name><surname>Pirone</surname><given-names>R</given-names></name><name><surname>Hoodless</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Tsui</surname><given-names>LC</given-names></name><name><surname>Bapat</surname><given-names>B</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Andrulis</surname><given-names>IL</given-names></name><name><surname>Thomsen</surname><given-names>GH</given-names></name><name><surname>Wrana</surname><given-names>JL</given-names></name><name><surname>Attisano</surname><given-names>L</given-names></name></person-group><article-title>MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma</article-title><source>Cell</source><year>1996</year><volume>86</volume><fpage>543</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">8752209</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80128-2</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thiagalingam</surname><given-names>S</given-names></name><name><surname>Lengauer</surname><given-names>C</given-names></name><name><surname>Leach</surname><given-names>FS</given-names></name><name><surname>Schutte</surname><given-names>M</given-names></name><name><surname>Hahn</surname><given-names>SA</given-names></name><name><surname>Overhauser</surname><given-names>J</given-names></name><name><surname>Willson</surname><given-names>JK</given-names></name><name><surname>Markowitz</surname><given-names>S</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><article-title>Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers</article-title><source>Nat Genet</source><year>1996</year><volume>13</volume><fpage>343</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">8673134</pub-id><pub-id pub-id-type="doi">10.1038/ng0796-343</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takagi</surname><given-names>Y</given-names></name><name><surname>Kohmura</surname><given-names>H</given-names></name><name><surname>Futamura</surname><given-names>M</given-names></name><name><surname>Kida</surname><given-names>H</given-names></name><name><surname>Tanemura</surname><given-names>H</given-names></name><name><surname>Shimokawa</surname><given-names>K</given-names></name><name><surname>Saji</surname><given-names>S</given-names></name></person-group><article-title>Somatic alterations of the DPC4 gene in human colorectal cancers in vivo</article-title><source>Gastroenterology</source><year>1996</year><volume>111</volume><fpage>1369</fpage><lpage>1372</lpage><pub-id pub-id-type="pmid">8898652</pub-id><pub-id pub-id-type="doi">10.1053/gast.1996.v111.pm8898652</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>MacGrogan</surname><given-names>D</given-names></name><name><surname>Pegram</surname><given-names>M</given-names></name><name><surname>Slamon</surname><given-names>D</given-names></name><name><surname>Bookstein</surname><given-names>R</given-names></name></person-group><article-title>Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas</article-title><source>Oncogene</source><year>1997</year><volume>15</volume><fpage>1111</fpage><lpage>1114</lpage><pub-id pub-id-type="pmid">9285566</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1201232</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>S</given-names></name></person-group><article-title>Alternative activation of macrophages</article-title><source>Nat Rev Immunol</source><year>2003</year><volume>3</volume><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">12511873</pub-id><pub-id pub-id-type="doi">10.1038/nri978</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name><name><surname>Locati</surname><given-names>M</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name></person-group><article-title>Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes</article-title><source>Trends Immunol</source><year>2002</year><volume>23</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">12401408</pub-id><pub-id pub-id-type="doi">10.1016/S1471-4906(02)02302-5</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crowther</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>NJ</given-names></name><name><surname>Bishop</surname><given-names>ET</given-names></name><name><surname>Lewis</surname><given-names>CE</given-names></name></person-group><article-title>Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors</article-title><source>J Leukoc Biol</source><year>2001</year><volume>70</volume><fpage>478</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">11590184</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pollard</surname><given-names>JW</given-names></name></person-group><article-title>Tumour-educated macrophages promote tumour progression and metastasis</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">14708027</pub-id><pub-id pub-id-type="doi">10.1038/nrc1256</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nesbit</surname><given-names>M</given-names></name><name><surname>Schaider</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>TH</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name></person-group><article-title>Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells</article-title><source>J Immunol</source><year>2001</year><volume>166</volume><fpage>6483</fpage><lpage>6490</lpage><pub-id pub-id-type="pmid">11359798</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dinapoli</surname><given-names>MR</given-names></name><name><surname>Calderon</surname><given-names>CL</given-names></name><name><surname>Lopez</surname><given-names>DM</given-names></name></person-group><article-title>The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene</article-title><source>J Exp Med</source><year>1996</year><volume>183</volume><fpage>1323</fpage><lpage>1329</lpage><pub-id pub-id-type="pmid">8666890</pub-id><pub-id pub-id-type="doi">10.1084/jem.183.4.1323</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oosterling</surname><given-names>SJ</given-names></name><name><surname>van der Bij</surname><given-names>GJ</given-names></name><name><surname>Meijer</surname><given-names>GA</given-names></name><name><surname>Tuk</surname><given-names>CW</given-names></name><name><surname>van Garderen</surname><given-names>E</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Meijer</surname><given-names>S</given-names></name><name><surname>van der Sijp</surname><given-names>JR</given-names></name><name><surname>Beelen</surname><given-names>RH</given-names></name><name><surname>van Egmond</surname><given-names>M</given-names></name></person-group><article-title>Macrophages direct tumour histology and clinical outcome in a colon cancer model</article-title><source>J Pathol</source><year>2005</year><volume>207</volume><fpage>147</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">16104052</pub-id><pub-id pub-id-type="doi">10.1002/path.1830</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsamandas</surname><given-names>AC</given-names></name><name><surname>Kardamakis</surname><given-names>D</given-names></name><name><surname>Ravazoula</surname><given-names>P</given-names></name><name><surname>Zolota</surname><given-names>V</given-names></name><name><surname>Salakou</surname><given-names>S</given-names></name><name><surname>Tepetes</surname><given-names>K</given-names></name><name><surname>Kalogeropoulou</surname><given-names>C</given-names></name><name><surname>Tsota</surname><given-names>I</given-names></name><name><surname>Kourelis</surname><given-names>T</given-names></name><name><surname>Makatsoris</surname><given-names>T</given-names></name><name><surname>Karavias</surname><given-names>D</given-names></name><name><surname>Scopa</surname><given-names>CD</given-names></name><name><surname>Bonikos</surname><given-names>DS</given-names></name><name><surname>Kalofonos</surname><given-names>HP</given-names></name><name><surname>Petsas</surname><given-names>T</given-names></name></person-group><article-title>The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival</article-title><source>Strahlenther Onkol</source><year>2004</year><volume>180</volume><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">15057430</pub-id><pub-id pub-id-type="doi">10.1007/s00066-004-1149-x</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guzinska-Ustymowicz</surname><given-names>K</given-names></name><name><surname>Kemona</surname><given-names>A</given-names></name></person-group><article-title>Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer</article-title><source>World J Gastroenterol</source><year>2005</year><volume>11</volume><fpage>1193</fpage><lpage>1195</lpage><pub-id pub-id-type="pmid">15754403</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bellone</surname><given-names>G</given-names></name><name><surname>Carbone</surname><given-names>A</given-names></name><name><surname>Tibaudi</surname><given-names>D</given-names></name><name><surname>Mauri</surname><given-names>F</given-names></name><name><surname>Ferrero</surname><given-names>I</given-names></name><name><surname>Smirne</surname><given-names>C</given-names></name><name><surname>Suman</surname><given-names>F</given-names></name><name><surname>Rivetti</surname><given-names>C</given-names></name><name><surname>Migliaretti</surname><given-names>G</given-names></name><name><surname>Camandona</surname><given-names>M</given-names></name><name><surname>Palestro</surname><given-names>G</given-names></name><name><surname>Emanuelli</surname><given-names>G</given-names></name><name><surname>Rodeck</surname><given-names>U</given-names></name></person-group><article-title>Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma</article-title><source>Eur J Cancer</source><year>2001</year><volume>37</volume><fpage>224</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">11166150</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(00)00391-9</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kouraklis</surname><given-names>G</given-names></name><name><surname>Kakisis</surname><given-names>J</given-names></name><name><surname>Theoharis</surname><given-names>S</given-names></name><name><surname>Tzonou</surname><given-names>A</given-names></name><name><surname>Glinavou</surname><given-names>A</given-names></name><name><surname>Raftopoulos</surname><given-names>J</given-names></name><name><surname>Karatzas</surname><given-names>G</given-names></name></person-group><article-title>Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer</article-title><source>Dig Dis Sci</source><year>2003</year><volume>48</volume><fpage>2284</fpage><lpage>2289</lpage><pub-id pub-id-type="pmid">14714614</pub-id><pub-id pub-id-type="doi">10.1023/B:DDAS.0000007864.24866.77</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwarte-Waldhoff</surname><given-names>I</given-names></name><name><surname>Schmiegel</surname><given-names>W</given-names></name></person-group><article-title>Smad4 transcriptional pathways and angiogenesis</article-title><source>Int J Gastrointest Cancer</source><year>2002</year><volume>31</volume><fpage>47</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">12622415</pub-id><pub-id pub-id-type="doi">10.1385/IJGC:31:1-3:47</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Katuri</surname><given-names>V</given-names></name><name><surname>Srinivasan</surname><given-names>R</given-names></name><name><surname>Fogt</surname><given-names>F</given-names></name><name><surname>Redman</surname><given-names>R</given-names></name><name><surname>Anand</surname><given-names>G</given-names></name><name><surname>Said</surname><given-names>A</given-names></name><name><surname>Fishbein</surname><given-names>T</given-names></name><name><surname>Zasloff</surname><given-names>M</given-names></name><name><surname>Reddy</surname><given-names>EP</given-names></name><name><surname>Mishra</surname><given-names>B</given-names></name><name><surname>Mishra</surname><given-names>L</given-names></name></person-group><article-title>Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>4228</fpage><lpage>4237</lpage><pub-id pub-id-type="pmid">15899814</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-4585</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isaksson-Mettavainio</surname><given-names>M</given-names></name><name><surname>Palmqvist</surname><given-names>R</given-names></name><name><surname>Forssell</surname><given-names>J</given-names></name><name><surname>Stenling</surname><given-names>R</given-names></name><name><surname>Oberg</surname><given-names>A</given-names></name></person-group><article-title>SMAD4/DPC4 expression and prognosis in human colorectal cancer</article-title><source>Anticancer Res</source><year>2006</year><volume>26</volume><fpage>507</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">16739311</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Rimm</surname><given-names>DL</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Shih</surname><given-names>WJ</given-names></name><name><surname>Reiss</surname><given-names>M</given-names></name></person-group><article-title>Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis</article-title><source>Cancer J</source><year>2003</year><volume>9</volume><fpage>302</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">12967141</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alazzouzi</surname><given-names>H</given-names></name><name><surname>Alhopuro</surname><given-names>P</given-names></name><name><surname>Salovaara</surname><given-names>R</given-names></name><name><surname>Sammalkorpi</surname><given-names>H</given-names></name><name><surname>Jarvinen</surname><given-names>H</given-names></name><name><surname>Mecklin</surname><given-names>JP</given-names></name><name><surname>Hemminki</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>S</given-names><suffix>Jr.</suffix></name><name><surname>Aaltonen</surname><given-names>LA</given-names></name><name><surname>Arango</surname><given-names>D</given-names></name></person-group><article-title>SMAD4 as a prognostic marker in colorectal cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>2606</fpage><lpage>2611</lpage><pub-id pub-id-type="pmid">15814640</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-1458</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Molberg</surname><given-names>K</given-names></name><name><surname>Albores-Saavedra</surname><given-names>J</given-names></name><name><surname>Lindberg</surname><given-names>G</given-names></name></person-group><article-title>Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease</article-title><source>Am J Pathol</source><year>2000</year><volume>157</volume><fpage>1105</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">11021814</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kouvidou</surname><given-names>C</given-names></name><name><surname>Latoufis</surname><given-names>C</given-names></name><name><surname>Lianou</surname><given-names>E</given-names></name><name><surname>Kouvatseas</surname><given-names>G</given-names></name><name><surname>Kakouri</surname><given-names>E</given-names></name><name><surname>Anagnostakis</surname><given-names>D</given-names></name><name><surname>Vrettou-Aravani</surname><given-names>V</given-names></name><name><surname>Betsi</surname><given-names>E</given-names></name><name><surname>Karatapanis</surname><given-names>S</given-names></name></person-group><article-title>Expression of Smad4 and TGF-beta2 in colorectal carcinoma</article-title><source>Anticancer Res</source><year>2006</year><volume>26</volume><fpage>2901</fpage><lpage>2907</lpage><pub-id pub-id-type="pmid">16886611</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deacu</surname><given-names>E</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>F</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Olaru</surname><given-names>A</given-names></name><name><surname>Sterian</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Schulmann</surname><given-names>K</given-names></name><name><surname>Berki</surname><given-names>A</given-names></name><name><surname>Kan</surname><given-names>T</given-names></name><name><surname>Abraham</surname><given-names>JM</given-names></name><name><surname>Meltzer</surname><given-names>SJ</given-names></name></person-group><article-title>Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>7690</fpage><lpage>7696</lpage><pub-id pub-id-type="pmid">15520171</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2082</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Wever</surname><given-names>O</given-names></name><name><surname>Mareel</surname><given-names>M</given-names></name></person-group><article-title>Role of tissue stroma in cancer cell invasion</article-title><source>J Pathol</source><year>2003</year><volume>200</volume><fpage>429</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">12845611</pub-id><pub-id pub-id-type="doi">10.1002/path.1398</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Michor</surname><given-names>F</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name><name><surname>Iwasa</surname><given-names>Y</given-names></name></person-group><article-title>Evolution of resistance to cancer therapy</article-title><source>Curr Pharm Des</source><year>2006</year><volume>12</volume><fpage>261</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">16454743</pub-id><pub-id pub-id-type="doi">10.2174/138161206775201956</pub-id></citation></ref></ref-list></back></article> 